Non-ST-Segment Elevation Myocardial Infarction
A 'mild' heart attack where a heart artery is partially blocked, causing heart muscle damage without the classic ECG changes seen in fully blocked arteries.
Emergency Management: If a patient with NSTEMI develops cardiogenic shock, life-threatening arrhythmias (VT/VF), or ongoing refractory ischemia, their status upgrades to an equivalent of a STEMI, requiring immediate emergent coronary angiography (< 2 hours).
Non-ST-segment elevation myocardial infarction (NSTEMI) is an acute coronary syndrome (ACS) characterized by ischemic myocardial necrosis. It is distinguished from STEMI by the absence of ST-segment elevation on the electrocardiogram (ECG), typically resulting from a partially occlusive coronary artery thrombus, causing subendocardial ischemia.
Detailed Overview
NSTEMI occurs when oxygen demand outstrips supply due to acute plaque rupture or erosion leading to thrombosis, but the vessel remains partially patent, or there is robust collateral circulation. Unlike unstable angina, NSTEMI involves actual myocardial death, evidenced by elevated cardiac biomarkers (Troponin). Management relies on risk stratification (e.g., TIMI or GRACE scores) to determine the timing of invasive angiography, accompanied by potent antiplatelet and antithrombotic therapies.
Epidemiology & Demographics
NSTEMI is the most common presentation of acute myocardial infarction, accounting for approximately 70% of all MI cases. Incidence increases with age and is more prevalent in patients with multiple comorbidities like diabetes and chronic kidney disease.
Etiological Mechanism
The primary etiology is the rupture or erosion of an atherosclerotic plaque in an epicardial coronary artery, leading to platelet aggregation and non-occlusive thrombus formation. Type 2 NSTEMI can occur from demand ischemia (e.g., severe anemia, sepsis, tachyarrhythmia) without acute plaque rupture.
Primary Causes
Coronary atherosclerosis with plaque rupture (Type 1 MI)
Supply/demand mismatch (Type 2 MI - e.g., tachycardia, anemia, hypotension)
Coronary artery spasm (Prinzmetal angina)
Coronary artery dissection
An atherosclerotic plaque containing a lipid-rich core and a thin fibrous cap ruptures, exposing subendothelial collagen and tissue factor. Platelets adhere, activate, and aggregate, triggering the coagulation cascade to form a fibrin mesh. In NSTEMI, the resulting thrombus is platelet-rich (white thrombus) and only partially occludes the vessel, or transiently occludes and spontaneously lyses. Blood flow is reduced but not completely cut off. The subendocardium, being the most distal tissue supplied and subjected to the highest wall tension, is the first to become ischemic and undergo necrosis, releasing intracellular proteins like Troponin into the bloodstream.
Diagnostic Criteria & Guidelines
Diagnosis requires: 1) Clinical symptoms of ischemia, PLUS 2) A rise and/or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit, PLUS 3) Absence of ST-segment elevation on ECG (may have ST depression, T wave inversion, or be normal).
Immediate medical therapy: Aspirin 324 mg chewed, Sublingual Nitroglycerin 0.4 mg q5min x3 for pain, High-intensity Statin (Atorvastatin 80 mg), and an Anticoagulant (Unfractionated Heparin infusion or Enoxaparin 1 mg/kg SQ BID). A P2Y12 inhibitor (Ticagrelor 180 mg load or Clopidogrel 300-600 mg load) is added. Beta-blockers (Metoprolol tartrate 25 mg PO) within 24 hours if no signs of heart failure or shock.
Second-Line & Adjunctive Therapy
Risk stratification determines invasive strategy. High-risk patients (refractory pain, hemodynamic instability, GRACE score >140) undergo an early invasive strategy (Coronary Angiography within 24 hours). Low-risk patients may undergo an ischemia-guided strategy (non-invasive stress testing first).
Surgical & Procedural Management
Percutaneous Coronary Intervention (PCI) with drug-eluting stent placement is the primary revascularization method. Coronary Artery Bypass Grafting (CABG) is indicated for left main disease, severe three-vessel disease, or in diabetics with complex anatomy.
Patient Counseling & Advice
Emphasize strict adherence to Dual Antiplatelet Therapy (DAPT - Aspirin + P2Y12 inhibitor) for at least 12 months post-stent to prevent stent thrombosis. Educate on using sublingual nitroglycerin for future chest pain and calling emergency services if pain is not relieved after 1 dose.
Follow-Up & Monitoring Schedule
Cardiology clinic visit within 1-2 weeks of discharge. Regular lipid checks (Target LDL < 55 mg/dL). Repeat echocardiogram if LVEF was reduced.
Preventive Strategies
Aggressive management of hypertension, diabetes, and hyperlipidemia. Daily low-dose Aspirin (81 mg) and statin therapy.
In-hospital mortality is lower for NSTEMI than STEMI. However, NSTEMI patients often have more comorbidities and multi-vessel disease, making their long-term (1-3 year) mortality risk similar or even higher than STEMI patients.